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Background: Directing autogenous Mesenchymal Stem Cell (MSC) to defect sites has a great 
promise in bone regeneration. We designed a MSC specific, bone affinity peptide (E7HA7) by 
conjugating E7 with a polyglutamate hydroxyapatite (HA) binding motif. We sought to 
characterize the in-vivo releasing pattern and bioactivity of E7HA7. Methods: HA discs were 
coated with fluorescent labeled peptides E7HA7, E7HA2 or E7 were subcutaneously implanted 
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in Sprague Dawley rats. In an ectopic bone formation model was used to test the in-vivo 
bioactivity of E7HA7 conjugated to DBM. Results: E7HA7 showed slower peptide release from 
scaffolds in comparison to other groups, being statistically significant at week 2 compared to E7, 
and to E7HA2 at week 4 and 8. In ectopic model, the medians for new bone formation in each 
group were: iDBM=0.041mm3, iDBM-E7=0.071mm3, aDBM=0.138mm3, and aDBM-
E7=0.192mm3. Conclusions: Conjugation of E7 to polyglutamate bone binding domain showed 
slow releasing kinetics and osteoinductive potential.  
 
Keywords: Mesenchymal Stem Cell, Regeneration, Hydroxyapatite, Demineralized Bone Matrix, 
Peptide 
  
 Introduction 
Periodontal Disease 
Periodontal disease is one of the most common inflammatory diseases affecting over 50% 
of adults in the United States1. It is characterized as inflammation of the supporting tissues of 
teeth, which can progressively lead to periodontal pocket formation, suppuration, fibrosis, 
destruction of alveolar bone and periodontal ligament (PDL), mobility and eventual tooth 
exfoliation. In a study by Becker et al, when periodontal disease remained untreated, patients 
continued to have progressive radiographic bone loss and increased in probing depth. When 
periodontally hopeless teeth were not treated, patients were at risk of losing 0.36/teeth per year2. 
However periodontal disease can be managed with numerous therapies including non-surgical 
therapy, surgical therapy, and regenerative methods. 
The primary etiological factor in periodontitis is bacterial biofilm and their products, 
which cause inflammatory reaction by the host. Eventually, with the continued host mediated 
destruction, patients begin to have an apical migration of the junctional epithelium leading to 
pocket formation and possible bone loss.  With bone loss and apical migration of the junctional 
epithelium, pocket formation will continue to propagate forming a favorable anaerobic 
environment for bacterial biofilm. In addition to the favorable environment for anaerobic 
bacterial species, the bone loss often creates osseous defects in between teeth that makes 
treatment even more challenging for the clinician. 
The goal of periodontal treatment is to arrest the progression of periodontal disease and if 
possible reverse some of the effects with regenerative therapies. Removal of the harmful 
bacterial biofilm is completed through scaling and root planing. Scaling and root planing utilizes 
periodontal scalers and curettes to mechanically remove plaque and calculus off tooth and root 
surfaces, and then smooth out root surfaces to remove infected dentin and cementum that can be 
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impregnated with etiological factors that cause inflammation. Scaling and root planing is the 
primary and initial modality of treating periodontitis, however, the effectiveness of the non-
surgical treatment can be limited by the severity of periodontal disease and numerous local 
factors such as cervical enamel projection (CEP), root grooves, enamel pearls, cemental tears, 
furcations, etc. The efficacy of scaling and root planing is dependent on the initial probing 
depths. In deep, > 6 mm pockets, only 32% of the surface were calculus free after Scaling and 
root planing group. On average, scaling and root planning was shown to reduce probing depths 
by 1.56 mm and have an attachment gain of 0.52 mm3. However, even with the reduction in 
probing depth and gains in attachment, long term studies have shown that over time non-surgical 
therapy is not as effective as surgical therapy especially as the severity of periodontal disease 
increases 4,5.  
Non-surgical therapy is the initial step for managing periodontal diseases, which usually 
results in a repair of the periodontium with the attachment of long junctional epithelium to root 
surface. The curetted root surface may be repopulated by 4 different types of cells: epithelial, 
gingival connective tissue, bone and PDL cells. Depending on the cells which repopulate the root 
surface, different attachments may form. Long junctional epithelium healing has no new CT 
attachment and is just epithelial downgrowth (reattachment). However, if new CT attachment is 
formed through repopulation by PDL, then new attachment can occur. Similar healing occurs 
through surgical therapy however there is increased probing depth reduction at the expense of 
attachment levels. In more severe cases of periodontitis intrabony defects, depending on the 
morphology of defects it can be treated with regeneration. The term regeneration is defined as 
the reconstitution of a lost or injured part, which in periodontics would be the reconstitution of 
the periodontal ligament, cementum and bone.  
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Guided Tissue Regeneration and Periodontal Regeneration 
Guided tissue regeneration attempts to regenerate the lost periodontal structure by 
excluding the epithelium from the root surface allowing for bone, cementum, and PDL to 
regenerate. The idea that the PDL has the ability to regenerate was originally proposed by 
Melcher where he hypothesized that the periodontium has four separate compartments of 
connective tissue (CT) in the periodontium: the gingival corium, periodontal ligament (PDL), 
cementum, and bone6,7. Therefore, for regeneration to occur, the regeneration of periodontium 
must come from the bone and PDL. The PDL tissue contains a population of Mesenchymal Stem 
Cells (MSCs) which are multipotent stromal cells that can differentiate into multiple cell 
lineages. Mesenchymal stem cells are essential for osteogenesis and cementogenesis in the 
development of the periodontium which give rise to cementoblasts, osteoblasts, fibroblasts, 
myofibroblasts, endothelial cells nerve cells and epithelial cells. The multipotentiality of MSCs 
is believed to be crucial for regeneration8.  
The regenerative potential of the periodontal ligament was demonstrated by Nyman in 
monkeys with guided tissue regeneration technique, which showed that by excluding the 
epithelium in surgically created defects, the preference was given to periodontal cells to 
repopulate the area and regenerate the periodontium9. The limitation of the study was that the site 
was not previously diseased and that the defects were created surgically. Gottlow, later 
demonstrated that with previously diseases root surfaces it was also possible to regenerate the 
periodontium10. With epithelial exclusion, coagulum is formed and inflammatory cells infiltrate 
the area removing necrotic tissue11. MSCs from nearby bone marrow and periodontal ligament 
then migrate into the defects and begin to differentiate into tissue specific cells such as 
osteoblasts, PDL cells and cementoblasts. At the same time, tissue specific extracellular matrix is 
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produced. With the formation of blood vessels more MSC’s are brought to the defect, with 
eventual regeneration of the periodontal complex. The origin of the regenerative cells was 
confirmed by Iglhaut through histologic and autoradiographic analysis, indicating that bone and 
PDL tissue compartments supply cells to a periodontal wound in surgically created periodontal 
spaces 12.  The mesenchymal stem cells embedded within the bone and PDL are the at the center 
of the regenerative events, and often these cells are considered as a reservoir for healing-
promoting factors because of their trophic and immune-modulatory activities13. The need for 
MSCs is vital for regeneration otherwise the defect will be dominated by fibrotic cells leading to 
non-functional scar tissue, referred to as tissue repair.  
Over the years numerous techniques have been developed to regenerate periodontal 
tissues, including placing graft substitute material within a periodontal defect in combination 
with some type of resorbable or non-resorbable periodontal membrane, membrane alone, bone 
substitute in combination with biological material, biological material alone, etc. Although 
successful results were observed, they are highly unpredictable and the outcome is still largely 
depend on defect morphology(depth, width, number of walls), particulate size, ability of surgeon, 
correct material chosen for the defect, stability of graft, ability for angiogenesis, sufficient space 
for progenitor cells to populate the area, and stability of the periodontal complex14.  In Froum’s 
study where osseous coagulum was compared versus open flap debridement it was showed that 
bone fill was an average 3.64mm in 3 wall defects, 3.21mm in 2 wall defects, and 2.42mm in 1 
wall defects, whereas open flap debridement showed 1.38mm, 1.03mm, and 0.16mm 
respectively15. Although the grafted sites were deeper in this study, it does show that the more 
bony walls a defect has the better regenerative potential is possible due to greater surface area 
and access to MSCs from the bone and periodontal ligament. Similarly, using Gore-tex 
 5 
membrane Cortellini showed that 3 wall defects were filled by 95±6.2%, 2 wall defects were 
filled by 82%±18.7% and 1 wall defects was only filled by 39 ± 62.4%. These results again show 
that the increased number of bony walls the better regenerative outcome is possible16. Lastly, in 
furcations, Murphy and Gunsolley demonstrated in their systematic reviews and meta-analysis 
that class 2 furcations have the best regenerative outcomes, due to the ability to have sufficient 
space to maintain and stabilize graft material within the sites17. It was found that within class 2 
furcations both membrane and graft material enhanced vertical probing depth reduction, 
horizontal attachment level, and horizontal open attachment level gain17. Often clinicians are 
faced with varying morphological defects that are not ideal. Such irregular defects present a 
significant challenge for regeneration, partly might due to a decreased access to mesenchymal 
cells from the neighboring bone and periodontal ligament.  
Bone Substitutes  
 Bone substitute materials vary from autografts (cortical ⁄ cancellous bone, bone marrow), 
allografts (demineralized freeze-dried ⁄ freeze-dried bone), xenograft, and alloplastic materials 
(ceramics, hydroxyapatite, polymers and bioglass). New bone formation can occur by three 
mechanisms utilizing bone substitute materials can occur by three mechanisms: osteogenesis 
osteoinduction, osteoconduction. Osteogenic potential is defined as the ability to have vital 
osteoblasts within the grafting material that allow for bone formation. Osteoinduction is defined 
as the stimulation of osteoprogenitor cells (mesenchymal cells) to differentiate into osteoblasts 
that produce new bone formation. Osteoconduction refers to the grafting material acting as a 
scaffold for new bone formation from host bone cells.  Autografts have osteogenic, 
osteoconductive and osteoinductive potential. Allografts have osteoconductive and 
osteoinductive potential depending on the amount of mineralization within the graft, and lastly 
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alloplastic materials are limited to a osteoconductive potential. In periodontal regeneration, 
autogenous bone and bone marrow is the “gold standard” of grafting because there are MSCs 
within the graft which can differentiate into multiple cell types favoring the regeneration process. 
However, the limitation to autogenous grafting is that often a second site is needed, increased 
patient morbidity, insufficient autogenous bone, and poor quality autogenous bone.  
 As a substitute to autogenous bone, allografts are a common substitute used to filled 
osseous defects and can come in a combination of mineralized freeze-dried bone allograft 
(FDBA) and demineralized freeze-dried bone allograft (DFBDA). In early regeneration studies 
DFDBA was used for periodontal defects because of its osteoinductive ability. Urist and Strates 
first demonstrated that demineralized bone has osteoinductive potential through bone formation 
in extraskeletal sites18, which led clinicians to believe that DFDBA is an excellent  material bone 
substitute. The osteoinductive potential is from remaining bone morphogenic proteins in the 
processed graft, where it was shown that BMP-2, BMP-4, and BMP-7 are present19. 
Osteoinductive capabilities of DFDBA often vary between tissue banks and same batches of 
graft material, which could be due to inactive proteins within the graft, insufficient quantities, 
processing methods, age of donor, and medical status 20,2122.  Initially it was believed that due to 
presence of BMP within DFDBA, the bone graft would be superior in regeneration, which was 
shown in early studies23, however based on meta-analysis and various clinical studies there was 
no difference in the ability to treat intrabony and furcal defects24–26. The lack in superiority of 
DFDBA over FDBA is due to the heterogeneous nature of the studies, processing methods used 
by different tissue banks, variance in surgical skill, etc   
A substitute to allografts and autografts are alloplasts, which are synthetic inert bone 
substitutes. A commonly used alloplast is hydroxyapatite which is a made of calcium phosphate, 
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the primary constituent of bone mineral. Alloplasts have been used for regeneration based on 
properties of being highly adsorptive and osteoconductive. Although numerous bone substitute 
grafts can be used for periodontal regeneration, they are often osteoconductive and not inductive 
and do not have the potential to induce neighboring MSCs for regeneration, therefore 
supplemental biological materials can be added to the graft to improve the osteoinductivity. 
Biologics  
 Although bone substitute materials are commonly used in periodontal defects, there is 
still clinical unpredictability, therefore additional materials such as biologics can be added to 
bone substitutes or be used alone for regeneration. The biologics can range from the delivery of 
stem cells or different recombinant proteins consisting of Enamel Matrix Derivative (EMD), 
platelet rich plasma (PRP), bone morphogenic proteins (BMP), platelet derived growth factor 
(PDGF), or synthetic peptides27 One of the most commonly used biologics is EMD, which is a 
protein/peptide mix derived from porcine teeth. EMD induces cementogenesis and is a tissue 
healing modulator that helps stimulate periodontal regeneration. EMD has been shown to be 
effective in periodontal regeneration alone or in combination with bone graft substitutes. Platelet 
derived growth factor (PDGF) is derived from platelets, macrophages, and osteoblasts. PDGF 
stimulates intracellular pathways for DNA and protein synthesis and stimulate cell proliferation. 
It has been used in both periodontal and periimplant defects. Although both EMD and PDGF 
have been shown to be effective in periodontal regeneration and healing, limitations remain 
regarding the application of growth factors. EMD has a gel like consistency and if primary 
closure of the defects is not obtained the displacement of the growth factors takes place and often 
the gel like consistency is not sufficient in maintaining space within the defect leading to soft 
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tissue collapse. Additionally, the varied results in literature may be due to a low efficiency in 
targeting MSCs to allow further expansion and functioning during the healing process. 
 Even with modern biologics, the degree of tooth-supporting tissue regeneration is still 
suboptimal and usually results in less than 50% bone regeneration and 20% horizontal defect 
fill28. One of the factors that makes regeneration unpredictable is the varying morphology that is 
encountered with each periodontal defect, inefficiency of directing MSCs into periodontal wound 
healing sites, and engraftment of MSCs which have made regeneration difficult29. Periodontal 
regeneration is not a passive process, but rather a dynamic process that includes processes such 
as early protein expression, cell apposition, remodeling and maturation of the healing site8. Cell 
based therapies and homing of mesenchymal cells to accelerate and capitalize on the dynamic 
process of regeneration have drawn increasing attentions in the field.  
Emerging Concepts  
Cell therapy is being intensively investigated for accelerating periodontal regeneration 
through direct delivery of stem cells, mainly MSCs, to the periodontal defects. MSCs from bone 
marrow (BMSCs) are the most widely studied partly because they are easily accessible. 
Transplantation of BMSCs induced periodontal regeneration that was characterized by new 
cementum, bone and PDL ligament formation in experimental periodontal defects in rats, rabbits, 
mini pigs, and dogs30. By cell-labeling techniques, the differentiation of exogenous BMSCs to 
cementoblasts, PDL fibroblasts, and alveolar bone osteoblasts was confirmed31,32. Although a 
few preclinical and clinical studies have suggested the potential of MSC cell therapy in 
periodontal regeneration, many challenges remain in current treatment strategies based on 
exogenous stem cells. For example, a sophisticated cell culture facility is commonly needed for 
cell expansion before clinical use. There will be difficulties in the transportation of cells if a 
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central culture facility is used. Other issues include the lack of cell sources, safety concerns 
regarding the use of animal serum and potential tumorigenic effects. Furthermore, only a small 
percentage of stem cells remain after weeks of engraftment29,33. Therefore, approaches to target 
endogenous MSCs in patients are highly desirable both from a clinical and financial standpoint. 
 Recently a MSC affinity peptide (E7, EPLQLKM) was discovered through phage display 
technology34. The peptide showed a high affinity to BMSCs across rat and human species. E7 
peptide has the ability to increase the homing and proliferation of MSCs36,37, enhance the 
infiltration rate of stem cells34, reduce inflammatory response35, and promote ligament-bone 
healing and cartilage regeneration35 . Covalent conjugation of E7 to polycaprolactone (PCL) and 
poly-L-lactide (PLLA) bio-polymers significantly enhanced the attachment of BMSCs to the 
material surface and increased cell spreading. The E7 functionalized biomaterial was also able to 
stimulate MSCs proliferation during in vitro culture.35
 
When bone marrow was cultured in the 
E7-conjugated cell culture devices, enrichment of MSCs was observed compared with those 
grown with E7, suggesting a use for MSC enrichment bio-incubators36.  
Recently, Lin group tested E7 peptide on human PDL cells against a scramble control 
(scramble sequence of E7) and DMSO to determine its affinity of PDL and BMSC cells. E7 was 
shown to have highest affinity for PDL progenitor cells and BMSC, and in addition E7 had a 
stronger affinity than RGD, a well investigated peptide of type 1 collagen. The affinity to PDL 
and BMSC was strong regardless of the modification of the terminal amino acid, suggesting a 
future protein engineering to modify the function of this peptide. Even though preliminary data 
shows strong affinity for PDL and BMSCs, from a clinical standpoint the addition of bone 
substitute material within periodontal defects allows space maintenance and tissue support for 
mesenchymal stem cells to migrate into the defect. Although it may seem logical to combine 
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peptides with bone grafts to induce greater bone growth, common issues with peptide therapy 
combined bone graft substitutes is the inability to have a controlled release of peptide. Often 
combination of growth factors with bone grafts results in a bolus release which can leading to 
immediate degradation and consumption of the peptide within a 24-hour period. In addition to 
the fact that growth factors have a very short half-life in vivo, superphysiological doses are 
commonly used in clinics. rhBMP-2 loading dose is usually a million times higher than 
physiological levels and many times higher than needed in non-human primates and mice.37 Such 
high dosages of growth factors are often related to various systemic side effects as well as high 
treatment cost. Therefore, a peptide that has the ability to have a controlled release and strong 
bone conjugation would be able to promote a sustained regeneration. 
As mentioned, hydroxyapatite is a widely used osteoconductive bone grafting material 
based on its similar structure to bone, and has been compatible with linking different peptides 
and proteins for bone regeneration38,39,40.  Numerous linking mechanisms to bone matrix have 
been identified from endogenous bone matrix proteins. For example, Osteocalcin41, Bone 
sialoprotein BSP42 and Osteonectin43 bind to bone through γ-carboxyglutamic acid41. Such 
mechanisms inspired researchers to develop bone binding peptides/proteins. Phosphorylated 
amino acids or negatively charged amino acid sequences such a poly-Asp chain44 have been 
utilized to modulate bioactive peptides for stronger retention to hydroxyapatite. One binding 
mechanism utilizing polyglutamic acid allows different peptides to conjugate to bone/bone graft 
materials and increase the binding strength by nearly ten times45, and allows for the retention of 
amino acids for up to 3 months in different allograft materials36. Studies have not only shown 
that by increasing the number of glutamate residues36 there is an increased binding strength to 
bone domains but by adjusting the number of glutamate residues, one can tune the release rate of 
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the amino acid. Utilizing the bone binding capabilities of polyglutamic acid and MSC homing 
ability of E7 peptide, we designed a novel peptide E7HA7 to improve the bioactivity of bone 
graft material by attracting and maintaining MSCs at the healing site. In this study, we 
investigated the in vivo bioactivity of this peptide.     
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Specific Aims 
In this two-part study, we first tuned E7-HA with two glutamate residues (E7HA2) and 
seven glutamate(E7HA7) residues to determine which peptide modification has the greatest 
retention with hydroxyapatite in vivo. In part 2, we tested whether E7HA7 enhances the 
osteoinductive potential Demineralized Bone Matrix (DBM) in a murine ectopic bone formation 
model. Our hypothesis is that a greater retention of peptide E7 will occur with the 
heptaglutamate residue based on the greater number of anionic sites from glutamate. In aim 2 our 
hypothesis is that the conjugation of E7HA7 with DBM will enhance the osteoinductivity of the 
bone substitute material.  
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Methods and Materials 
 
Aim 1: E7- Peptide In-vivo Release Kinetics 
Experimental Design 
All procedures performed on animals followed protocols approved by the institutional Animal 
Care and Use Committee (IACUC) at Virginia Commonwealth University. Synthetic 
hydroxyapatite (HA) discs were used as a model to mimic mineralized bone grafts. One E7 
peptide without any glutamate modifications was attached to the E7 directly and two HA binding 
domains, one with seven glutamates (E7HA7) and the other with two glutamates (E7HA2), were 
linked to the bone grafts. All peptides were labeled with Fluorescein isothiocyanate (FITC) 
fluorescent marker at the N terminus for in-vivo fluorescence detection.  
Peptide Synthesis 
Peptide synthesis: The following custom peptides were synthesized from Genscript Co. 
(Piscataway, NJ): 
Name Sequence 
HA Disc None (control) 
E7 EPLQLKMCK-(FITC) 
E7HA-2 EEEPLQLKMCK-(FITC) 
E7HA-7 EEEEEEEEPLQLKMCK-(FITC) 
 
In order to facilitate the conjugation of FITC to the peptides, a cysteine is added to N terminus. 
All peptides were reconstituted in DMSO to achieve a concentration of 2 mg/mL, aliquoted and 
stored at −20°C. HA disks (5mm in diameter, 1.6mm in thickness) that designed for 96-well 
plate were obtained from 3D-Biotek (Hillsborough, NJ, USA). To track binding and release 
kinetics, variations of these peptides were synthesized to contain Fluorescein (FITC) tags.  
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Peptide coating 
The peptide solutions were added to HA scaffold in sterile 96 well plate (100 ul/well) with 
concentrations of 0.2 mM with continuous agitation at room temperature.  After 24 hours, 
supernatants were aspirated completely and surfaces were briefly washed three times with 
phosphate buffered saline (PBS) for 5 min with agitation. The HA discs were dried and stored 
under sterile conditions at room temperature in a dark environment until needed.  
Surgery 
All procedures performed on animals followed protocols approved by the Institutional Animal 
Care and Use Committee (IACUC approved protocol number: AD10001162) at Virginia 
Commonwealth University. Animals were ordered two weeks ahead of time to allow rats to 
acclimate to the environment and were fed ad libitum. Rats were randomized by independent 
examiner and were weighed prior to anesthesia, at week 2,4 and 8. Weights were stabilized and 
did not fluctuate significantly during examination, no signs of stress were present to the animals.  
General anesthesia was administered to Sprague–Dawley rats, using methoxyfluorane for all 
surgical procedures. All the animals were administered with Buprenophine SR LAB to release 
the pain stress caused by the surgery. Two one cm midsagittal incisions were made on the dorsa, 
and two subcutaneous pockets were created with hemostats via blunt dissection on each side of 
the incision (Figure 1). Discs with different coatings were randomized per animal by a separate 
examiner and surgeon was blinded to the identity of the discs.  Four discs were implanted into 
each rat, each disc from a separate group. Once discs were inserted, sites were closed with 
staples and swabbed with iodine at incisions lines. A total of 13 rats had four discs implanted 
subcutaneously.  
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In-vitro Fluorescence Imaging  
In vitro Fluorescent images were taken at 0,2,4,8 weeks. All fluorescent images were captured 
with CRi Maestro In-vivo spectral imaging system (Cambridge Research & Instrumentation, US) 
(Woburn, MA) (Figure 1). At each time point except week 0, four animals were euthanized using 
CO2, once animal was euthanized two midsagittal incisions were made in similar area as 
previous surgery. Scaffolds were retrieved with the surrounding tissue (about 4 mm thick tissue 
around the scaffold was retrieved with the scaffold) and immediately soaked into 10 % neutral-
buffered formalin. Discs were immediately placed in dark container so that fluorescence marker 
would not be altered by ambient light. At 2w, 4w and 8w, residual peptides within the HA 
scaffolds were measured with Maestro imaging system (Figure 1). There were 4 scaffolds for 
each treatment group at 2-week and 4-week time points, and 5 scaffolds/treatment group for 8-
week time point. In total, there were 52 scaffolds and 13 rats.  
Aim 2: Osteoinductive potential of DBM in Combination with E7 
Sample preparation  
In this study, Demineralized Bone Matrix Allograft (DBM) was procured from the 
Musculoskeletal Transplant Foundation (Edison, NJ). All samples provided to the surgical and 
evaluation team were coded to blind the reviewers to the tissue bank source as well as donor age 
and sex. Four different groups of DBM were tested; Active DBM (positive control) where active 
protein factors were present on the bone matrix from the normal tissue processing from the tissue 
bank. All tissue banks follow a general system that involves cleaning, defatting, and disinfecting 
cortical bone; grinding the defatted bone to particle sizes between 400 and 1000 mm; 
demineralizing the bone particles in dilute hydrochloric acid solutions, resulting in a residual 
calcium content of <8% per the American Association of Tissue Banks standards; and freeze-
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drying the final product46. Active DBM from the same lot was heated for twenty-four hours at 
105˚C to inactivate any biologically active protein factors present and served as Inactive DBM 
(negative control). E7HA7 was conjugated to both and Inactive and active DBM matrix. Particle 
size was kept between 400-1000 microns, which is the typical size bone graft used for 
periodontal grafting.  Capsules were filled with 20mg of active or inactive DBM with/without E7 
peptides. Capsules were used to facilitate implantation and help localized the bone graft and 
prevent displacement in-situ. All samples were prepared under aseptic conditions and were 
stored at room temperature until samples were ready for implantation.  
Experimental Design 
The second part of the study was conducted under a protocol approved by the Institutional 
Animal Care and Use Committee at Virginia Commonwealth University. Sixteen 8-week-old 
nude athymic mice were divided into four groups: Active DBM (aDBM), Active DBM-E7 
(aDBM-E7), Inactive DBM (iDBM), and Active DBM-E7 (iDBM-E7).  
Implantation Protocol 
An ectopic bone formation model was used to test the bioactivity of E7HA7 and the 
enhancement of osteoinductivity when combined with demineralized bone matrix. Athymic nude 
mice were anesthetized by inhalation of 5% isoflurane gas. A 1cm incision along gastrocnemius 
muscle was made and a longitudinal split with blunt dissection was created per leg. One gelatin 
20mg capsule containing a variation of DBM was inserted into the muscle pouch and was closed 
with a wound clip (N=2/animal) (Figure 3). 8 implants were placed in each group with a total of 
16 animals.  
 The mice were housed in appropriate conditions based on their immunocompromised 
status and were given food and water ad libitum for 35 days. This time period was chosen based 
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on previous experiments demonstrating that 35 days was sufficient time for osteoinductive 
activity to take place in this animal model. Animals were sacrificed at 35 days using carbon 
dioxide asphyxiation. The hind limbs were disarticulated and immediately placed into 10% 
formalin solution for future histological and morphometric assessment.  
Morphometric Analysis 
The ability of the samples to induce new bone were quantitatively analyzed by two separate 
blinded examiners using Bruker Skyscan 1173 MicroCT (Billerica, MA) (Figure 3). Each 
disarticulated hind leg was placed inside a plastic test tube fitted with cotton gauze to stabilize 
the leg from moving during imaging. The plastic test tube was placed on the platform in the 
machine and imaged. Once raw images were created, a superior and inferior threshold was made 
for each image to exclude any areas that could have bone fragments or noise from disarticulation. 
The examiner went through each cross section of each microCT slice, a region of interest was 
made around the long bones of the leg to eliminate to subtract the region of interest to determine 
the amount of new bone formation in each sample (Figure 4, Figure 5, Figure 6, Figure 7). 
Similar imaging parameters were selected for each sample and new bone formation was 
determined by new bone volume formation in mm3.  
Histomorphometric analysis 
Samples were commercially processed (Histion, Everett, WA, USA). Femurs were embedded in 
methyl methacrylate, and one ground section from each specimen was stained with Hematoxylin 
and Eosin staining. Sections were imaged with an AxioCam MRc5 camera and Axio Observer 
Z.1 and analyzed using ZEN 2012 Blue Edition software (Carl Zeiss Microscopy, Oberkochen, 
Germany). 
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Statistical analyses 
Part 1 
The study is a two-way design (four treatments and 4 time periods), with animals observed 
across time. This within-animal dependence is taken into account in the analysis. The 
interventions are compared using a repeated-measures mixed-model two-way ANOVA. 
Fluorescence is severely skewed and so the log-transformed values are used for analyses. The 
least-squared mean estimated values for each group are back-transformed to the original scale, 
yielding geometric mean values. Differences between treatments are identified at each week 
using pre-specified contrasts. All analyses were performed using SAS software (JMP pro version 
13.2, SAS version 9.4, SAS Institute Inc., Cary NC). 
Part 2 
The study is a two-way design (Active vs Inactive and E7HA7 yes vs no), with the interventions 
assigned to either the left or right leg of the animal. This within-animal dependence is taken into 
account in the analysis. The interventions are compared using a repeated-measures mixed-model 
two-way ANOVA. The bone volume (in mm3) is severely skewed and so the log-transformed 
values are used for analyses. The least-squared mean estimated values for each group are back-
transformed to the original scale, yielding geometric mean values. Differences between the four 
groups are identified by Tukey’s honestly significantly different multiple comparison procedure 
(at alpha = 0.05). 
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Results 
 
Weights among the animals remained stable throughout the experiment. No animal deaths were 
observed throughout the experiment, and all animals tolerated the procedures well.  
Aim 1: Retention of E-7 Peptide on HA discs 
Qualitatively, at week 0 discs coated with E7-HA2-FITC had the strongest fluorescence signal, 
especially on the perimeter of the discs. Qualitatively, E7-HA7-FITC groups had the highest 
fluorescence intensity at 2,4, and 8 weeks. Interestingly, fluorescence was mainly noted on 
perimeter of discs. The fluorescence intensity of each group at the four time periods is shown in 
(Figure 8). Fluorescence values are strongly skewed with higher variability occurring at brighter 
intensity. Based on the skewed intensity a two-way ANOVA analysis analyzed the log-
transformed values to equalize the variability within groups. The back-transformed values for 
each group are summarized in (Table 1). In the peptide releasing study, all three peptide groups 
had statistically stronger fluorescence signals at all the time points compared to control discs. 
E7HA7 coated scaffolds had stronger fluorescent signals at all three time points compared to 
other groups, indicating a longer retention and stronger affinity for HA scaffolds. E7HA7 
showed slower peptide release from scaffolds in comparison to other groups, being statistically 
significant at week 2 compared to E7, and to E7HA2 at week 4 and week 8(Figure 8,Figure 9). 
Aim 2: The osteogenic potential of bone graft material combined with E7HA peptide 
New Bone Volume Formation 
The median values for new bone formation are: iDBM=0.041mm3, iDBM-E7=0.071mm3, 
aDBM=0.138mm3, and aDBM-E7=0.192mm3 (Figure 10). As is typical with volume 
measurements, the values were skewed. The two-way repeated-measures ANOVA was 
performed on the log-transformed bone levels. There was a significant difference between the 
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active and inactive groups (P=0.008), but no significant difference between the E7 vs E7HA7 
groups (P=0.187). Although new bone formation was greater in aDBM-E7, significant difference 
was only found when compared to the iDBM group (Table 2) .When comparing controls, aDBM 
vs iDBM, aDBM had a greater bone formation than iDBM, however the difference was not 
statistically significant.  The addition of E7HA7 increased the bone volume 1.48 times (P=0.48) 
in the inactive DBM group and 1.98 times (P=0.23) in the active DBM group, but the additive 
benefit did not reach statistical significance. 
The results of the multiple comparison procedure are shown in Table 3. As mentioned 
earlier, the only statistically significant difference of new bone formation was between aDBM-
E7 vs. iDBM, where aDBM had 5.6 times more new bone formation present (p =0.03). It is 
interesting to point out that, if we only compare the active DBM to inactive DBM (without 
E7HA7 coating), although more bone formation (2.82 times as high) was seen in the active DBM 
group, the difference was not statistically significant (P=0.27).  
Histological Observations 
All photomicrographs were screened, and one representative sample was chosen from 
each group to be included for qualitative assessment. Photomicrographs of Inactive samples 
showed DBM particles, surrounded by a combination of connective tissue, adipose tissue, and 
muscles tissues. The inactive samples did not show any new bone formation within the samples. 
No new bone formation was demonstrated by a homogeneous color of bone particle with the 
absence of osteoclasts, osteoblasts, and hematopoietic cells surrounding the periphery of the graft 
or within lacunae. No inflammatory cells were noted in the inactive samples surrounding bone 
particles (Figure 11). A general trend noticed in active samples was fewer DBM particles 
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present, possibly indicating that heat treatment of the bone graft could have led to increased 
resorption of the DBM particles 
Active groups demonstrated DBM particles, surrounded by a combination of connective 
tissue, adipose tissue, and muscles tissues. When comparing both active and inactive samples 
there was more presence of bone graft in the active samples, indicating less resorption of the 
bone graft. Although a larger quantity of bone graft was present in active samples, there was 
minimal to no new bone formation present seen by uniform color of the residual graft material 
and lack of bone marrow, immature bone, and hematopoietic cells (Figure 12).  
The addition of E7 to inactive groups showed similar morphology to inactive groups, 
however the addition of E7 showed less resorption of graft materials and the presence of a 
greater number of particles in comparison to iDBM samples by themselves (Figure 13). More 
robust osteoinduction was present in active samples in combination with E7 peptide. Presence of 
Ossicles (bone-like tissue surrounding an area of bone marrow-like tissue) was present in 
aDBM-E7 samples (Figure 14, 
Figure 15). Ossicles are indicative of mature bone formation. In addition, presence of 
osteocytes and hematopoietic cells was present in aDBM-E7 samples. Since limited new bone 
formation was present in the aDBM alone, and more mature bone formation was present with the 
addition of E7 peptide in several samples is a possible indication of osteoinductive enhancement 
of the DBM.  
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Discussion 
 
Numerous bone substitute materials are used for periodontal regeneration, each one with their 
positive and negative attributes. Limitations of synthetic HA are that the alloplastic material has 
good osteoconductive properties but lacks the osteoinductive properties. However, surface 
functionalization of HA through the addition of osteoinductive molecules can enhance the 
regenerative outcomes.  
The success in periodontal and bone regenerative procedures is still highly dependent on 
the defect morphology and regenerative potential of the patient. Previous studies have shown that 
there are numerous modalities for enhancing osteoinductivity of bone material, such as the 
delivery of stem cells, platelet rich plasma, and recombinant proteins (Platelet Derived Growth 
Factor BB and bone morphogenic proteins). Although there are benefits to adding various 
enhancing products, the molecules are passively adsorbed to the surface and have low binding 
capacity to the grafting material, limiting effective release control kinetics. To enhance bone 
binding and release kinetics various mechanisms mimicking the endogenous bone matrix 
proteins, such as GLA protein, osteonectin and bone sialoprotein, have been identified. A bone 
binding motif consisting of negatively charged amino acids such a glutamic acid is one of them.  
One of the first groups to identify the affinity of glutamic acid to HA crystals was Fujisawa, who 
showed that through degradation of osteonectin, the residual binding residues were rich in 
glutamic acid45. In later studies, Fujisawa compared the binding of osteoblastic cells to HA 
coated BSP, osteonectin, bovine serum albumin and Glu7-Pro-Arg-Gly-Asp- Thr (E7TPRGDT). 
E7TPRGDT was used because it contained both a putative hydroxyapatite- binding sequence and 
the RGD sequence, a cell binding motif. E7TPRGDT being 1/50 the size of BSP had similar 
 23 
ability to recruit osteoblastic cells as BSP, and the dissociation constant was 500x times greater 
than that of BSP.  
The Culpepper group has also demonstrated the enhanced coupling of polyglutamic acids 
to bioactive peptides for enhanced retention and controlled release in vitro and in vivo models. 
DGEA (Asp-Gly-Glu-Ala), a collagen derived peptide were synthesized with variable length 
polyglutamate chains (diglutamate (E2), tetraglutamate (E4), and heptaglutamate (E7) and 
adsorbed on to HA discs and allograft particles and retention was determined36. In all mediums 
and assays E7>E4>E2 had increased peptide loading and retention after 5 days36. The bound 
peptide released ranged from in E7-DGEA was <10%  after 5 days in Saline agitation and ~35% 
in serum containing media, while DGEA alone was nearly 90-100% released in both medias 
after a 5 day period36. In similar medias, improved retention was noted on HA discs vs Allograft, 
however different binding substrates (HA discs vs allograft particle) was used.  
In Polini’s study comparing release kinetics of E7 (polyglutamate), Osteocalcin (OCN), 
and salivary statherin (N7) adsorbed to similar HA discs used in our study, the results were 
comparable to release kinetics present in our study. Overall E7 had the greatest retention 
compared to OCN and N7. When these retentive molecules were tested on their own at a 1-
month time period, 75% of E7, 30% of OCN, and 25% of N7 was still retentive on the HA 
scaffolds47. When E7 was combined with osteogenic molecules such as Osteogenic Growth 
peptide (OGN) and Bone morphogenic Protein -7 (BMP-7) the addition of osteogenic molecules 
did not affect peptide retention and at a 1-month time point nearly 60% of the peptide was 
retained. The combination of an osteogenic molecules with E7 did not affect the binding and 
releasing properties of E7.  
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 Similarly, in our study when comparing varying polyglutamate chains, the E7HA7 had 
the greatest retention on discs over an 8-week period.  E7HA7 showed slower peptide release 
from being statistically significant at week 2 compared to E7, and to E7HA2 at week 4 and week 
8. Culpepper showed that DGEA alone had quickest release, nearly 100% released by 5 days and 
E2 had quicker releasing at all time points in comparison to E7. In our current experiment over 
an 8-week period although E7HA7 had greatest retention, interestingly E7 alone vs E7HA2 had 
greater retention at 4 and 8-week time points. However, this was not statistically significant. In 
addition, when examining the release curves of the various groups it is evident that at the 1-week 
time point E7 and E7HA2 were nearly one hundred percent released, where E7HA7 still has 
approximately 50% of peptide bound to the HA discs. Reasons for greater retention could be due 
to uneven distribution of peptide along the HA surfaces, where more would accumulate on the 
edge of the discs as opposed to the center of the discs. Greater accumulation along the edge of 
the discs could be speculated to having a greater surface roughness and increased surface area for 
binding for the bioactive peptides within the study. In addition to greater accumulation on the 
edges, the stronger fluorescence intensity seen from the edge of the discs could also wash out the 
fluorescent intensity that may be present on the middle of the discs. Quantification of peptide 
release in our study was difficult due determine to a different model used in comparison to the 
Culpepper studies, where they used serum containing media or saline media, our studies used a 
subcutaneous environment of rats making it difficult to have a standard to compare direct 
release.  
 In another study by the Culpepper group they examined the effects of Heptaglutamate 
domain coupled with DGEA peptide on HA discs and HA discs coupled with electrospun 
scaffolds48. Similarly, in their studies, in a subcutaneous model DGEA coupled with 
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Heptaglutamate had the greatest retention on HA discs coupled with and without electrospun 
scaffolds, in comparison to DGEA alone. The results indicate that surface modification of bony 
substrates with bioactive peptides can serve as a vehicle for long term release of regenerative 
molecules. Modulating the release of the bioactive peptides, E7 has the potential to recruit 
autologous bone marrow derived, periodontal, and pulpal stem cells to the periodontal defect for 
regeneration.  
 Numerous experiments including ours have shown increased retention of peptides to both 
hydroxyapatite and allograft materials through ionic coupling of polyglutamate domains to 
endogenous bone matrix proteins. Demineralized allograft materials, another popular graft for 
regeneration due to its exposed osteoinductive proteins on the surface have been shown to be 
successful in periodontal regeneration. However, the osteoinduction potential often varies among 
various demineralized allografts due to inactive proteins within the graft, insufficient quantities, 
processing methods, residual calcium levels, age of donor, and medical status. To our 
knowledge, the addition of modified E7 (EPLQLKM) peptide to DBM, is one of the first in-vivo 
experiments to test the additive effects to osteoinductivity of E7 to DBM.  
 The additive effect of the E7HA7 to DBM increased bone volume about 1.5 times in the 
inactive DBM and about two times in the active DBM. Although the osteoinductive 
enhancement of E7 is not statistically significant, it is suggestive of an enhancement of the 
osteoinductive potential. The lack of statistical significance for new bone formation could be due 
to several reasons. As shown initially by Fujisawa, when heptaglutamate was coupled with 
PRGDT, there was a positive correlation with peptide binding with calcium ions, and negative 
correlation with phosphate ions, measured through fluorometry45. Based on the AATB, the DBM 
used in this experiment has less than 8% residual calcium present according to the manufacturer 
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website which suggests that only a small percentage of E7 heptaglutamate would have been 
bound to the graft. Additionally Culpepper, demonstrated that, with electrospun 
polycaprolactone (PCL) scaffolds compared to HA discs under constant wash for 7 days, PCL 
alone was insufficient for retaining E7-DGEA, and that HA is needed to facilitate binding48.  
 The intent of demineralization of allograft is to expose the proteoglycan/collagen matrix 
and protein factors such as bone morphogenic proteins. Zhang, showed that FDBA 
demineralized with hydrochloric acid, depending on the demineralization time the residual 
calcium by weight can drop from ~32% to ~1% if demineralized up to 300 minutes22. In 
addition, Zhang demonstrated that osteoinductivity of DBM can also vary based on particle size. 
The particle size with most osteoinductive potential ranged from 500-710 microns, whereas 
particles less than 250 microns had significantly reduced osteoinductive potential compared to 
other particle sizes22. Demineralized bone was used in this intramuscular model so that new 
calcification/osteogenesis could be quantified through micro-CT imaging.  
The weak enhancement of E7 to the osteoinductive potential of DBM and range of bone 
volume formations can be explained due to several reasons. Based on histology from our study it 
was evident that very weak new bone formation and osteoinduction was present in the active 
DBM group. According to Schwartz et al, the variability and lack of osteoinductivity could be 
due to processing methods of the tissue bank, insufficient time for the new bone formation to 
occur, batch used in the experiment is not osteoinductive21. The particular batch from our study 
could not have been as inductive as other batches, Schwartz found that 18% of the batches had 
no osteoinductivity, and 40% had only moderate inductivity20. Lastly, insufficient time could 
have resulted in less bone formation. In Schwartz 1996 study bone formation was assessed at day 
28 and day 56, where a larger amount of new bone formation was evident at day 56 in 
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comparison to day 28. Increased bone volume formation at a later time point was due to a less 
robust osteoinductive effect at an earlier time point21. There is a possibility that a longer time 
could have resulted in more new and mature bone formation for the active group with and 
without E7 with a longer incubation time. Although hardly any new and mature bone formation 
was seen in aDBM group, the combination of E7 peptide, did enhance formation of new and 
mature bone. The presence of new and mature bone formation presents in several samples only 
in the aDBM-E7 group, indicate that there is an enhancement of osteoinductivity with E7 
peptide.  
 The variability in particle size could account for the broad range of volumetric 
measurements among groups. Although uniform amount of bone was used among each group, 
the small variance in particle size could affect osteogenesis and osteoinduction. The weak 
osteoinductive enhancement of E7 could also be due to the residual calcium particles left over 
within the graft. Since demineralized bone was used, the low concentration of calcium within the 
graft could account for a weak binding affinity of E7 peptide to the demineralized bone, which 
would affect osteoinductive enhancement. Although a high binding affinity was shown for HA 
discs and E7HA7, no attempts at this time have been made to quantify affinity or retention of 
E7HA7 on demineralized bone. Additionally one of the difficulties in mesenchymal stem cell 
homing is the low efficiency and engraftment of endogenous mesenchymal cells29. As previously 
shown, Bone Marrow Derived Mesenchymal Cells have the ability to differentiate into dental 
progenitor cells, the highest engraftment of mesenchymal cells was seen in pulpal and 
periodontal tissues as opposed to lung, liver, and adipose tissue32. The reason for higher 
engraftment was due to continuous remodeling of periodontal tissue, a connective pathway 
between the bone marrow cavity and periodontium of the mandible, and higher expression of 
 28 
SDF-1 protein in dental mesenchymal tissues32. Therefore, based on location of particulate 
placement as shown in other studies, it may be difficult to home the necessary osteoblasts needed 
for osteogenesis. 
There are several limitations that apply to this study. In both portions of the experiment a 
larger number of samples within each group could have been used yielding a stronger result. In 
the second portion of the study, affinity and retention of DBM particulate in combination with 
E7 BMSC affinity peptide could have been examined in-vitro to determine binding capabilities 
and affinities. Additionally, a mineralized bone graft could have been compared to a 
demineralized bone graft to see if there was an additive benefit of E7 to the bone graft. Although 
there are limitations to the current model used to determine the benefit of E7 for osteogenesis, 
future studies will use periodontal defects to determine the ability of E7 to home in mesenchymal 
stem cells.  
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Conclusion 
 
Conjugation of E7 to polyglutamate bone binding domain showed long –lasting releasing 
kinetics from hydroxyapatite scaffolds. Based on the results, we can conclude that E7HA7 
promotes a stronger affinity to the Hydroxyapatite scaffold, with improved retention and 
controlled release. The conjugation of E7HA7 peptide to inactive and active DBM slightly 
enhanced the osteoinductivity potential of both allografts. Thus, E7HA7 may be used to enhance 
bone regeneration for guided tissue regeneration procedures in the future, however further 
studies need to be conducted.  
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Tables 
Table 1. Fluorescence Intensity by Peptide coating group at each Week 
Peptide Fluorescence intensity (au) 
Coating Geo. Mean   95% CI 
 Week 0 (n=4) 
Control 9.1  2.3 35.8 
E7-FITC 12,339.6 a 3,127.5 48,685.5 
E7HA2-FITC 29,518.9 a 7,481.7 116,466.2 
E7HA7-FITC 15,689.2 a 3,976.5 61,901.3 
 Week 2 (n=4) 
Control 2.3  0.6 9.0 
E7-FITC 145.2 a 36.8 573.1 
E7HA2-FITC 925.8 a 234.6 3,653.4 
E7HA7-FITC 4,224.7 a,b 1,070.8 16,668.6 
 Week 4 (n=4) 
Control 0.7  0.2 2.9 
E7-FITC 132.9 a 33.5 526.7 
E7HA2-FITC 46.7 a 11.8 184.1 
E7HA7-FITC 613.1 a,c 155.4 2,418.8 
 Week 8 (n=5) 
Control 1.8  0.5 6.0 
E7-FITC 152.4 a 44.7 520.4 
E7HA2-FITC 77.4 a 22.7 264.1 
E7HA7-FITC 540.5 a,c 158.3 1,844.6 
Notes: Least-squares mean estimated values from a repeated-measures mixed-model ANOVA 
were back-transformed to the original units to yield geometric means. Differences were 
identified by specific contrasts. 
 
Table 2. New bone volume, by groups 
  New bone volume (mm
3)  
Activity E7HA7 Estimate  * 95% CI p-value 
Inactive no 0.034 a 0.015 0.077  
 yes 0.050 
a,b 0.022 0.114  
  ratio 1.482   0.460 4.773 0.4846 
Active no 0.095 a,b 0.042 0.217  
 yes 0.188 
b 0.082 0.429  
  ratio 1.976   0.614 6.364 0.2336 
* The superscript values after the geometric mean estimate indicate group differences. Groups 
sharing the same superscript are not significantly different, by Tukey’s HSD (P<0.05). 
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Table 3. Paired comparisons between groups 
Comparison Ratio 95% CI Adjusted p-value 
Active no vs. Active yes 0.51 0.10 2.46 0.6117  
Active no vs. Inactive no 2.82 0.58 13.71 0.2736  
Active no vs. Inactive yes 1.90 0.39 9.25 0.6525  
Active yes vs. Inactive no 5.57 1.15 27.09 0.0312  
Active yes vs. Inactive yes 3.76 0.77 18.28 0.1170  
Inactive no vs. Inactive yes 0.67 0.14 3.28 0.8889   
Note: Differences on the log-scale, when back-transformed to the original scale are interpreted as 
the ratio of the groups compared. Active=active DBM; inactive=inactive DBM; yes=with 
E7HA7 peptide; no=no E7HA7 peptide. 
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Figures 
Figure 1: Disc Implantation in Animals and Fluorescent Imaging for Aim 1  
 
 
 
Schematic representation of subcutaneous implantation of hydroxyapatite discs and fluorescent 
imaging  
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Figure 2:  In-vivo Fluorescence Readings a t 0,2,4, and 8 Weeks 
 
 
 
Figure 3: Sky Scan 1173 Micro-CT and Gastrocnemius Implantation Protocol 
 
Surgical Implantation of gelatin capsules containing Demineralized Bone Matrix into 
gastrocnemius muscle of athymic nude mice 
  
0 weeks   2 weeks     4 weeks       8 weeks  
E7HA7 peptide coated scaffolds qualitatively have stronger fluorescent signals at 2,4,8 weeks indicating 
longer retention and stronger affinity for HA discs. Strongest fluorescence can be noted on peripheries of 
disks. (n=4 or 5) 
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Figure 4: Active DBM MicroCT Ectopic Bone Formation  
 
MicroCT rendering of ectopic bone formation. New bone formation can be denoted inside red 
circle.  
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Figure 5: Inactive DBM MicroCT Ectopic Bone Formation  
 
 
MicroCT rendering of ectopic bone formation. New bone formation can be denoted inside red 
circle.   
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Figure 6: Active DBM E7-Heptaglutamate MicroCT Ectopic Bone Formation  
 
MicroCT rendering of ectopic bone formation. New bone formation can be denoted inside red 
circle.  
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Figure 7: Inactive DBM E7-Heptaglutamate MicroCT Ectopic Bone Formation  
 
MicroCT rendering of ectopic bone formation. New bone formation can be denoted inside red 
circle.  
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Figure 8: Fluorescent Intensity by Peptide Coating Group at Each Week 
 
 
 
 
 
 
 
 
The raw fluorescent intensity of each of the groups at the four-time periods is shown in Figure 8: 
Fluorescent Intensity by Peptide Coating Group at Each Week. 
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Figure 9: Fluorescence Intensity by Peptide Coating Group at Each Week 
 
 
 
Within each week, differences between the four treatments are identified as follows: The “a” superscript 
identifies treatments with values significantly different than the control. The “b” superscript identifies 
differences as compared to E7-FITC. The “c” superscript identifies differences as compared to E7HA2-
FITC. 
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Figure 10: New Bone Volume (mm3) in Ectopic Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
The new bone volume levels in the 16 animals is shown in the boxplots of Figure 10. The median values for 
the four groups were as follows: Inactive=0.041025 mm3, Inactive E7=0.07135 mm3, Active=0.137985 
mm3, and Active E7=0.191515 mm3 
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Figure 11: Representative Inactive DBM Histology Sample 
Photomicrographs of iDBM, sample showing DBM particles, surrounded by a combination of 
connective tissue, adipose tissue, and muscles tissues with lack of new bone formation. (stained 
with hematoxylin and eosin) 
 
Figure 12: Representative Active DBM Histology Sample 
Photomicrographs of aDBM sample showing DBM particles, surrounded by a combination of 
connective tissue, adipose tissue, and muscles tissues with lack of new bone formation. (stained 
with hematoxylin and eosin) 
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Figure 13: Representative Inactive DBM-E7 Histology Sample 
 
Photomicrographs of iDBM-E7 samples showed DBM particles, surrounded by a combination of 
connective tissue, adipose tissue, and muscles tissues with lack of new bone formation.  
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Figure 14: Representative Active DBM-E7 Histology Sample
 
 
Figure 15: Active DBM-E7 Histology New Bone Formation
 
Photomicrograph of ossicle formed after intramuscular implantation of DBM 5weeks. Note the 
Ossicle formed (arrow), New Bone (N), bone marrow (M), Graft (G), Connective Tissue (C). 
(stained with hematoxylin and eosin) 
 
Photomicrographs of aDBM-E7 showing DBM particles, surrounded by a combination of 
connective tissue, adipose tissue, and muscles tissues. aDBM-E7 samples showing the 
presence of ossicles (bone-like tissue surrounding an area of bone marrow-like tissue) in 
the red and black boxes. 
 
